<<  Back

Harvard Apparatus, Inc. Acquires Hugo Sachs Elektronik

Dec 01,1999
Harvard Apparatus, Inc. Acquires Hugo Sachs Elektronik

Harvard Apparatus, Inc. of Holliston, Massachusetts USA, announces the acquisition of Hugo Sachs Elektronik of March - Hugstetten, Germany.

Hugo Sachs, founded in 1960, is the market leader in the design, manufacture and distribution of perfusion systems including associated hardware and software products primarily used in pharmacology, cardiology and physiology for the testing of new drugs.

This acquisition strengthens HAI’s position in this very important area of drug development. In addition, the strong market position of Hugo Sachs in Germany will provide an excellent channel for the distribution of all of HAI’s products. Likewise HAI’s strong market position in the US will strengthen Hugo Sachs' position in that market. The Hugo Sachs products will be included in the new HAI catalog, which is due to be released in March.

Hugo Sachs will continue to operate out of its current facility in March - Hugstetten, Germany and will trade under the name of Hugo Sachs Elektronik - Harvard Apparatus GmbH.

Harvard Apparatus designs, manufactures and distributes a broad range of products used in new drug development including technologies for molecular, cellular, tissue and in-vivo research.

For further information please contact Chane Graziano, CEO or David Green, President at 800-272-2775 or (508) 893-8999.



Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.